

Outline of talk

Questions:

- What is GOLD?
- How common is COPD?
- What is it?
- How do the new GOLD guidelines 2017 change things?
- How do I distinguish COPD from asthma? .
- Conclusions .

The Global Initiative for Chronic Obstructive Lung Disease (GOLD)





- January 1997:
 - COPD experts from several countries met in Brussels, Belgium, including representatives of the National Heart, Lung and Blood Institute (NHLBI, USA) and the World Health Organization (WHO). They recommended establishment of a panel with expertise on a wide variety of COPD-related topics to prepare an evidence-based document on COPD. ο.
- 2001: GOLD initiative launched in collaboration with NHLBI and WHO. Project supported by unrestricted educational grants from many pharmaceutical companies
- Goals of GOLD:
 - 1. To increase awareness of COPD and decrease morbidity and mortality from this disease
 2. To improve prevention and management of COPD through a concerted worldwide effort

 - 3. To encourage a renewed research interest in COPD





- COPD is currently the fourth leading cause of death in the world.
- COPD is projected to be the 3rd leading cause of death by 2020.
- More than 3 million people died of COPD in 2012, accounting for 6% of all deaths globally.
- Globally, the COPD burden is projected to increase in coming decades because of continued exposure to COPD risk factors and aging of the population.






































GOLD 2017: Identifying and treating comorbidities is important in patients with **COPD**

- COPD often co-exists with other diseases that may have a significant impact on health status and prognosis
- Cardiovascular disease is a major comorbidity in COPD The most frequent and most important co-morbid disease
- Other common co-morbidities include skeletal muscle dysfunction, metabolic syndrome, osteoporosis, depression, anxiety and lung cancer
- Co-morbidities should be actively sought and treated appropriately





GOLD 2017: Changed role for spirometry Post-bronchodilator spirometry is required for the diagnosis and assessment of COPD But: assessing the degree of reversibility of airflow limitation (e.g. measuring FEV₁ before and after bronchodilator or corticosteroids) to inform therapeutic decisions is no longer recommended Spirometry remains key in the diagnosis,







GOLD spirometry gradir	5	Spirometry: summary
Table 2.4. Classification of airflow limitation severity in COPD (Based on In patients with FEV/FVC = 0.70:	t-bronchodilator FEV,)	Table 2.6. Role of spirometry P Diagnosis Assessment of severity of airflow obstruction (for prognosis)
GOLD 1: Mild FEV ₁ ≥ 80% predicted		 Follow-up assessment
GOLD 2: Moderate 50% ≤ FEV ₁ < 80% predict		» Therapeutic decisions.
GOLD 3: Severe 30% ≤ FEV ₁ < 50% predict		 Pharmacological in selected circumstances (e.g., discrepancy between spirometry and level of symptoms).
BOLD 4: Very Severe FEV, < 30% predicted		Consider alternative diagnoses when symptoms are disproportionate to degree of airflow obstruction. Non-pharmacological (e.g., interventional procedures). Identification of rapid decline.












	Patient A	Patient B
FEV ₁ (% predicted)	<30%	<30%
CAT score	18	18
Exacerbations in the past 12 months	0	3
GOLD 2016 classification	D	D
GOLD 2017 classification ¹	Group B	Group D
being classified as GOLD B than		
 More than 50% of patients pre (based on airflow limitation alo GOLD B² 		

















GOLD 2017: Dual bronchodilator treatment is the preferred initial therapy for patients in Group D GOLD recommends LABA/LAMA as primary-choice treatment for Group D patients¹ LABA/LAMA has demonstrated superiority versus bronchodilator monotherapy and LABA/LS in exacerbation prevention^{2,3}

- and LABA/ICS in exacerbation prevention^{2,3}

 LABA/ICS may be first choice in patients with a history of and/or features
- suggestive of asthma-COPD overlap1 Treatment should be escalated to triple therapy in patients who experience further exacerbations despite treatment with LABA/LAMA or LABA/ICS1
- There is currently no evidence to support the efficacy of triple vs LABA/LAMA
 If further exacerbations develop despite treatment with triple therapy, the addition of a macrolide or roflumilast* may be considered¹
- (*roflumilast not available in Australia)
- GOLD also suggests the withdrawal of ICS if exacerbations persist on triple therapy

FEV, = forced explatory volume in 1 second ODL9 = Obtain instance for drawin Obsences ung Disease; ICS = inhaled conficosteroid IL-GOLD2027 DISA = instances requires the strug-acting multicativity antagonat 2. Wednichs JA, et al. Itemp 1 Med 2021 2. Wednichs JA, et al. Itemp 1 Med 2021


<image><complex-block><section-header><complex-block><complex-block><complex-block><complex-block><complex-block><complex-block><complex-block><complex-block><complex-block>


Differential diagnosis


Diagnosis	Suggestive Features
COPD	Onset in mid-life.
	Symptoms slowly progressive.
	History of tobacco smoking or exposure to other types of smoke.
Asthma	Onset early in life loften childboodl.
	Symptoms vary widely from day to day.
	Symptoms worse at night/early morning.
	Alleray, rhinitis, and/or eczema also present.
	Family history of asthma.
	Obesity openistence.
Congestive Heart Failure	Chest X-ray shows dilated heart, pulmonary edema.
congestite freure runare	Pulmonary function tests indicate volume restriction, not airflow limitation.
Bronchiertasis	Large volumes of purulent soutum.
	Commonly associated with bacterial infection.
	Chest X-ray[CT shows bronchial dilation, bronchial wall thickening.
Tuberculosis	Onset all ages.
	Chest X-ray shows lung infiltrate.
	Microbiological confirmation.
	High local prevalence of tuberculosis.
Obliterative Bronchiolitis	Onset at younger age, nonsmokers,
Obliterative Bronchiolitis	May have history of rheumatoid arthritis or acute fume exposure.
	May have history of meumatoid arthritis or acute turne exposure. Seen after lung or hone marrow transplantation.
Diffuse Panbronchiolitis	CT on expiration shows hypodense areas.
Diffuse Panbronchiolitis	Predominantly seen in patients of Asian descent.
	Most patients are male and nonsmokers.
	Almost all have chronic sinusitis
	Chest X-ray and HRCT show diffuse small centrilobular nodular opacities and hyperinflation.
smoked may develop COPD	arracteristic of the respective discases, but are not mandatory. For example, a person who has neve (especially in the developing world where other risk factors may be more important than eigarette riop in adult and even in elderly patients.




















Table 5.8. Interventions that reduce the freque	ncy of COPD exacerbations	
Intervention class	Intervention	
Bronchodilators	LABAs	
	LAMAs	
	LABA + LAMA	
Corticosteroid-containing regimens	LABA + ICS	
	LABA + LAMA + ICS	
Anti-inflammatory (non-steroid)	Roflumilast	
Anti-infectives	Vaccines	
	Long term macrolides	
Mucoregulators	N-acetylcysteine	
-	Carbocysteine	
Various others	Smoking cessation	
	Rehabilitation	
	Lung volume reduction	

Summary: GOLD 2017

- LAMAs in fashion
- LABAs secondin-command
- GCS out except for asthma & asthma /COPD overlap
- Exacerbation treatment unchanged but downtitrate afterwards
- Remember prevention!

